Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360779 | 0.86 | ALDH1A1 (0.60) | NPSR1ALDH1A1USP2HPGDSMN1; SMN2 | |
| SCHEMBL13746186 | 0.85 | NPSR1 (0.72) | NPSR1ALDH1A1USP2HPGDTDP1 | |
| SCHEMBL8372164 | 0.84 | MEN1 (0.61) | NPSR1ALDH1A1USP2HPGDTSHR | |
| SCHEMBL12993901 | 0.84 | ALDH1A1 (0.67) | ALDH1A1USP2TDP1TSHRCYP3A4 | |
| SCHEMBL3321589 | 0.84 | NPSR1 (0.52) | NPSR1ALDH1A1USP2HPGDTSHR | |
| SCHEMBL27734242 | 0.83 | ALDH1A1 (0.66) | NPSR1ALDH1A1USP2HPGDCYP3A4 | |
| SCHEMBL13745563 | 0.83 | ALDH1A1 (0.67) | NPSR1ALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL13745754 | 0.83 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL13061265 | 0.83 | ALDH1A1 (0.62) | NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL13745506 | 0.81 | ALDH1A1 (0.70) | ALDH1A1TDP1TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | NPSR1 4272/4885ALDH1A1 2630/4885USP2 2578/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | NPSR1 4212/4885ALDH1A1 2281/4885USP2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.